Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED FEBRUARY 2016. Refer to TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | certolizumab pegol (Cimzia®) | ||
| Formulation | 200 mg solution for injection | ||
| Reference number | 1211 | ||
| Indication | Treatment of adult patients with severe active axial spondyloarthritis, comprising: adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs); and adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance (MRI), who have had an inadequate response to, or are intolerant to NSAIDs |
||
| Company | UCB Pharma Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 3114 | ||
| NMG meeting date | 10/09/2014 | ||
| AWMSG meeting date | 08/10/2014 | ||
| Ratification by Welsh Government | 30/10/2014 | ||
| Date of issue | 31/10/2014 | ||
| NICE guidance | TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
||